Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$54.59
+4.1%
$52.34
$34.87
$78.48
$5.27B1.741.89 million shs1.24 million shs
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$2.34
-3.9%
$1.34
$0.91
$2.46
$271.52M2.131.85 million shs1.83 million shs
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$151.53
+1.3%
$131.12
$115.66
$160.18
$15.23B0.341.17 million shs886,158 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$56.68
-3.2%
$51.06
$23.30
$66.06
$3.53B2.221.34 million shs632,727 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-4.83%+0.15%+5.47%+7.55%+52.98%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
+6.11%+94.40%+111.30%+113.16%+143.00%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
+1.75%+13.61%+14.28%+5.94%+23.08%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-1.66%+0.15%+16.80%+18.91%+78.58%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$54.59
+4.1%
$52.34
$34.87
$78.48
$5.27B1.741.89 million shs1.24 million shs
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$2.34
-3.9%
$1.34
$0.91
$2.46
$271.52M2.131.85 million shs1.83 million shs
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$151.53
+1.3%
$131.12
$115.66
$160.18
$15.23B0.341.17 million shs886,158 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$56.68
-3.2%
$51.06
$23.30
$66.06
$3.53B2.221.34 million shs632,727 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-4.83%+0.15%+5.47%+7.55%+52.98%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
+6.11%+94.40%+111.30%+113.16%+143.00%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
+1.75%+13.61%+14.28%+5.94%+23.08%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-1.66%+0.15%+16.80%+18.91%+78.58%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.56
Moderate Buy$65.9419.20% Upside
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
2.25
Hold$4.5087.11% Upside
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2.82
Moderate Buy$183.7520.83% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.75
Moderate Buy$56.57-0.13% Downside

Current Analyst Ratings Breakdown

Latest CRSP, NBIX, FATE, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetBuy$140.00 ➝ $155.00
5/6/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Boost Price TargetBuy$80.00 ➝ $82.00
5/6/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetEqual Weight$185.00 ➝ $191.00
5/6/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetBuy$242.00 ➝ $246.00
5/6/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetOutperform$176.00 ➝ $180.00
5/6/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Reiterated RatingBuy$175.00
5/6/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetOverweight$190.00 ➝ $207.00
5/6/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetOutperform$166.00 ➝ $176.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$55.00 ➝ $60.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOutperform$50.00 ➝ $65.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
UpgradeMarket PerformOutperform$70.00
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$1M5,335.46N/AN/A$18.81 per share2.94
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$6.65M42.08N/AN/A$1.80 per share1.34
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$2.86B5.35$5.18 per share29.33$33.89 per share4.49
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$409.48M8.61N/AN/A$7.31 per share7.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%5/11/2026 (Estimated)
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$136.32M-$1.15N/AN/AN/A-2,051.08%-55.02%-38.05%5/12/2026 (Estimated)
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$478.60M$6.4923.4325.770.7421.55%19.79%13.82%N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%N/A

Latest CRSP, NBIX, FATE, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q1 2026
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.29N/AN/AN/A$1.49 millionN/A
5/4/2026Q1 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
3/31/2026Q1 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A-$1.28N/A-$1.28N/A$1.46 million
2/26/2026Q4 2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.27-$0.27N/A-$0.27$1.20 million$1.37 million
2/13/2026Q4 2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.15-$1.37-$0.22-$1.37$4.72 million$0.86 million
2/11/2026Q4 2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$2.36$1.88-$0.48$1.48$804.21 million$805.50 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/AN/AN/AN/AN/A
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.32
17.97
13.32
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/A
5.79
5.79
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/A
2.93
3.30
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
3.37

Institutional Ownership

CompanyInstitutional Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
97.54%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
92.59%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
4.30%
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
4.74%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4.60%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
46096.45 million92.30 millionOptionable
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
550116.28 million110.77 millionOptionable
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2,000100.55 million95.96 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable

Recent News About These Companies

Twist Bioscience (TWST) Gets a Buy from Guggenheim
Twist Bioscience Corp (TWST) Climbed on Earnings Beat
Twist Bioscience Q2 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$54.58 +2.17 (+4.13%)
As of 03:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Fate Therapeutics stock logo

Fate Therapeutics NASDAQ:FATE

$2.34 -0.10 (-3.91%)
As of 03:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Neurocrine Biosciences stock logo

Neurocrine Biosciences NASDAQ:NBIX

$151.53 +1.94 (+1.30%)
As of 03:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$56.68 -1.86 (-3.17%)
As of 03:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.